Publications by authors named "S Meterissian"
Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1 loss in melanoma remains understudied. NF1 has a RAS GTPase-activating protein (GAP) function; however, studies also support NF1 RAS-independent tumor-suppressor functions.
View Article and Find Full Text PDFImportance: Metastatic breast cancer (MBC) poses a substantial clinical challenge despite advancements in diagnosis and treatment. While tissue biopsies offer a static snapshot of disease, liquid biopsy-through detection of circulating tumor DNA (ctDNA)-provides minimally invasive, real-time insight into tumor biology.
Objective: To determine the association between ctDNA and survival outcomes in patients with MBC.
Importance: Between 5% and 10% of breast cancer cases are associated with an inherited germline pathogenic or likely pathogenic variant (GPV) in a breast cancer susceptibility gene (BCSG), which could alter local and systemic therapy recommendations. Traditional genetic testing criteria misses a proportion of these cases.
Objective: To evaluate the prevalence and clinicopathological associations of GPVs in 2 groups of BCSGs among an ethnically diverse cohort of women with newly diagnosed breast cancer.
Background And Purpose: Preoperative partial breast irradiation (PBI) is a novel technique that can be used in patients with early-stage breast cancer with the goal of limiting the irradiated breast volume, toxicity and number of fractions. The aim of this trial is to assess the toxicity, surgical, oncologic and cosmetic outcomes of preoperative PBI.
Materials And Methods: In this single-arm phase II trial, we enrolled women ≥ 60 years, with unifocal low-risk breast invasive ductal carcinoma (cT1N0, grade 1-2, ER+, Her2-).
Article Synopsis
- The study investigates the link between margin status and local recurrence-free survival (LRFS) in breast cancer patients who had breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC).
- It analyzed data from 544 female patients, finding that 41.2% achieved a pathologic complete response (pCR), which resulted in a significantly higher 5-year LRFS compared to those with residual disease.
- The results showed no significant difference in LRFS based on margin width or the number of close margins among patients with residual disease, indicating that margin status may not be as crucial as previously thought.